Facility Dialysate Calcium Practices and Clinical Outcomes Among Patients Receiving Hemodialysis: A Retrospective Observational Study

Background Some US dialysis facilities have reduced default dialysate calcium concentrations from 2.5 mEq/L to lower levels. There has been no rigorous systematic examination of the effects of such a reduction on clinical and biochemical outcomes. Study Design Retrospective cohort study. Setting &am...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of kidney diseases 2015-10, Vol.66 (4), p.655-665
Hauptverfasser: Brunelli, Steven M., MD, MSCE, Sibbel, Scott, PhD, MPH, Do, Thy P., PhD, MPH, Cooper, Kerry, MD, Bradbury, Brian D., DSc
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 665
container_issue 4
container_start_page 655
container_title American journal of kidney diseases
container_volume 66
creator Brunelli, Steven M., MD, MSCE
Sibbel, Scott, PhD, MPH
Do, Thy P., PhD, MPH
Cooper, Kerry, MD
Bradbury, Brian D., DSc
description Background Some US dialysis facilities have reduced default dialysate calcium concentrations from 2.5 mEq/L to lower levels. There has been no rigorous systematic examination of the effects of such a reduction on clinical and biochemical outcomes. Study Design Retrospective cohort study. Setting & Participants Medicare-eligible patients who received in-center hemodialysis at a large dialysis organization in January 2008 to December 2010. Predictor Facility conversion from predominant use (≥75% patients) of 2.50-mEq/L dialysate calcium to predominant use of lower dialysate calcium concentrations versus maintenance of predominant use of 2.50-mEq/L dialysate calcium. Outcomes All-cause and cause-specific mortality and hospitalization, laboratory markers of metabolic bone disease, and drug utilization. Measurements Hierarchical mixed linear and Poisson models were fit to compare pre- to postconversion differences in outcomes between converter and matched control facilities. Results, expressed as relative rate ratios (RRRs) and delta-delta (change in mean values), were estimated for early (months 0-2) and late (months 3-12) postconversion to allow for possible latent effects. Results Facility conversion was associated with greater rates of hospitalization for heart failure exacerbation (late RRR, 1.27 [95% CI, 1.06-1.51]), hypocalcemia (early RRR, 1.19 [95% CI, 1.05-1.35]; late RRR, 1.39 [95% CI, 1.20-1.60]), and intradialytic hypotension (early RRR, 1.07 [95% CI, 1.02-1.11]; late RRR, 1.05 [95% CI, 1.01-1.10]), but no differences were observed for all-cause mortality or hospitalization rates. Facility conversion was also associated with comparative temporal decreases in serum calcium level, increases in serum phosphate and parathyroid hormone levels, and increases in use of phosphate binders, vitamin D, and calcimimetics. Limitations Possible residual confounding, generalizability beyond Medicare patients uncertain. Conclusions There are potential safety concerns associated with the default use of dialysate calcium concentrations < 2.50 mEq/L, as well as biochemical evidence of poorer disease control despite associated greater medication use. Individualization of dialysate calcium concentration rather than predominant use of dialysate calcium concentrations < 2.50 mEq/L should be considered.
doi_str_mv 10.1053/j.ajkd.2015.03.038
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1716934090</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0272638615006423</els_id><sourcerecordid>1716934090</sourcerecordid><originalsourceid>FETCH-LOGICAL-c481t-76610191e0d8564e5c8e2951213f62d8bb8cc87750cc5c8aa3f06800196bedfe3</originalsourceid><addsrcrecordid>eNp9kt2KFDEQhYMo7rj6Al5ILr3pMT_d6YyIMIyuKyzM4up1SCfVkt7-GZPugX4A39tqZ3YvvBACgapzDqmvQshrztacFfJds7bNvV8Lxos1k3j0E7LihZCZ0lI_JSsmSpEpqdUFeZFSwxjbSKWekwuh0CPKfEV-X1kX2jDO9FOw7ZzsCHRnWxemjt5G68bgIFHbe7prQx-cbel-Gt3QYXXbDf1PemvHAP2Y6DdwEI4BS9fQDf5vXEjv6RY7YxzSATDtCHRfJYhHdA09pt2Nk59fkme1bRO8Ot-X5MfV5--76-xm_-XrbnuTuVzzMSuV4oxvODCvC5VD4TSITcEFl7USXleVdk6XZcGcw561smZKM7SoCnwN8pK8PeUe4vBrgjSaLiQHbWt7GKZkeMnVRuZsw1AqTlKHT08RanOIobNxNpyZBb9pzILfLPgNk3g0mt6c86eqA_9oeeCNgg8nAeCUxwDRJIf0HPgQEY_xQ_h__sd_7O68lXuYITXDFJEpzmGSMMzcLR9g2T8vGFO5kPIPy9CswQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1716934090</pqid></control><display><type>article</type><title>Facility Dialysate Calcium Practices and Clinical Outcomes Among Patients Receiving Hemodialysis: A Retrospective Observational Study</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Brunelli, Steven M., MD, MSCE ; Sibbel, Scott, PhD, MPH ; Do, Thy P., PhD, MPH ; Cooper, Kerry, MD ; Bradbury, Brian D., DSc</creator><creatorcontrib>Brunelli, Steven M., MD, MSCE ; Sibbel, Scott, PhD, MPH ; Do, Thy P., PhD, MPH ; Cooper, Kerry, MD ; Bradbury, Brian D., DSc</creatorcontrib><description>Background Some US dialysis facilities have reduced default dialysate calcium concentrations from 2.5 mEq/L to lower levels. There has been no rigorous systematic examination of the effects of such a reduction on clinical and biochemical outcomes. Study Design Retrospective cohort study. Setting &amp; Participants Medicare-eligible patients who received in-center hemodialysis at a large dialysis organization in January 2008 to December 2010. Predictor Facility conversion from predominant use (≥75% patients) of 2.50-mEq/L dialysate calcium to predominant use of lower dialysate calcium concentrations versus maintenance of predominant use of 2.50-mEq/L dialysate calcium. Outcomes All-cause and cause-specific mortality and hospitalization, laboratory markers of metabolic bone disease, and drug utilization. Measurements Hierarchical mixed linear and Poisson models were fit to compare pre- to postconversion differences in outcomes between converter and matched control facilities. Results, expressed as relative rate ratios (RRRs) and delta-delta (change in mean values), were estimated for early (months 0-2) and late (months 3-12) postconversion to allow for possible latent effects. Results Facility conversion was associated with greater rates of hospitalization for heart failure exacerbation (late RRR, 1.27 [95% CI, 1.06-1.51]), hypocalcemia (early RRR, 1.19 [95% CI, 1.05-1.35]; late RRR, 1.39 [95% CI, 1.20-1.60]), and intradialytic hypotension (early RRR, 1.07 [95% CI, 1.02-1.11]; late RRR, 1.05 [95% CI, 1.01-1.10]), but no differences were observed for all-cause mortality or hospitalization rates. Facility conversion was also associated with comparative temporal decreases in serum calcium level, increases in serum phosphate and parathyroid hormone levels, and increases in use of phosphate binders, vitamin D, and calcimimetics. Limitations Possible residual confounding, generalizability beyond Medicare patients uncertain. Conclusions There are potential safety concerns associated with the default use of dialysate calcium concentrations &lt; 2.50 mEq/L, as well as biochemical evidence of poorer disease control despite associated greater medication use. Individualization of dialysate calcium concentration rather than predominant use of dialysate calcium concentrations &lt; 2.50 mEq/L should be considered.</description><identifier>ISSN: 0272-6386</identifier><identifier>EISSN: 1523-6838</identifier><identifier>DOI: 10.1053/j.ajkd.2015.03.038</identifier><identifier>PMID: 26015274</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aged ; Biomarkers - blood ; Calcium - analysis ; Calcium - blood ; Cause of Death ; Cohort Studies ; dialysate calcium concentration ; dialysate composition ; End-stage renal disease (ESRD) ; Female ; Follow-Up Studies ; heart failure ; Heart Failure - etiology ; Heart Failure - mortality ; Hemodialysis Solutions - adverse effects ; Hemodialysis Solutions - chemistry ; Hemodialysis Units, Hospital ; Humans ; hypocalcemia ; intradialytic hypertension ; Kidney Failure, Chronic - blood ; Kidney Failure, Chronic - mortality ; Kidney Failure, Chronic - therapy ; Linear Models ; Male ; Medicare ; metabolic bone disease ; Middle Aged ; mortality ; Myocardial Infarction - etiology ; Myocardial Infarction - mortality ; Nephrology ; Poisson Distribution ; Prognosis ; Renal Dialysis - adverse effects ; Renal Dialysis - methods ; Retrospective Studies ; Risk Assessment ; secondary hyperparathyroidism ; Stroke - etiology ; Stroke - mortality ; Survival Analysis ; Treatment Outcome ; United States</subject><ispartof>American journal of kidney diseases, 2015-10, Vol.66 (4), p.655-665</ispartof><rights>National Kidney Foundation, Inc.</rights><rights>2015 National Kidney Foundation, Inc.</rights><rights>Copyright © 2015 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c481t-76610191e0d8564e5c8e2951213f62d8bb8cc87750cc5c8aa3f06800196bedfe3</citedby><cites>FETCH-LOGICAL-c481t-76610191e0d8564e5c8e2951213f62d8bb8cc87750cc5c8aa3f06800196bedfe3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0272638615006423$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26015274$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Brunelli, Steven M., MD, MSCE</creatorcontrib><creatorcontrib>Sibbel, Scott, PhD, MPH</creatorcontrib><creatorcontrib>Do, Thy P., PhD, MPH</creatorcontrib><creatorcontrib>Cooper, Kerry, MD</creatorcontrib><creatorcontrib>Bradbury, Brian D., DSc</creatorcontrib><title>Facility Dialysate Calcium Practices and Clinical Outcomes Among Patients Receiving Hemodialysis: A Retrospective Observational Study</title><title>American journal of kidney diseases</title><addtitle>Am J Kidney Dis</addtitle><description>Background Some US dialysis facilities have reduced default dialysate calcium concentrations from 2.5 mEq/L to lower levels. There has been no rigorous systematic examination of the effects of such a reduction on clinical and biochemical outcomes. Study Design Retrospective cohort study. Setting &amp; Participants Medicare-eligible patients who received in-center hemodialysis at a large dialysis organization in January 2008 to December 2010. Predictor Facility conversion from predominant use (≥75% patients) of 2.50-mEq/L dialysate calcium to predominant use of lower dialysate calcium concentrations versus maintenance of predominant use of 2.50-mEq/L dialysate calcium. Outcomes All-cause and cause-specific mortality and hospitalization, laboratory markers of metabolic bone disease, and drug utilization. Measurements Hierarchical mixed linear and Poisson models were fit to compare pre- to postconversion differences in outcomes between converter and matched control facilities. Results, expressed as relative rate ratios (RRRs) and delta-delta (change in mean values), were estimated for early (months 0-2) and late (months 3-12) postconversion to allow for possible latent effects. Results Facility conversion was associated with greater rates of hospitalization for heart failure exacerbation (late RRR, 1.27 [95% CI, 1.06-1.51]), hypocalcemia (early RRR, 1.19 [95% CI, 1.05-1.35]; late RRR, 1.39 [95% CI, 1.20-1.60]), and intradialytic hypotension (early RRR, 1.07 [95% CI, 1.02-1.11]; late RRR, 1.05 [95% CI, 1.01-1.10]), but no differences were observed for all-cause mortality or hospitalization rates. Facility conversion was also associated with comparative temporal decreases in serum calcium level, increases in serum phosphate and parathyroid hormone levels, and increases in use of phosphate binders, vitamin D, and calcimimetics. Limitations Possible residual confounding, generalizability beyond Medicare patients uncertain. Conclusions There are potential safety concerns associated with the default use of dialysate calcium concentrations &lt; 2.50 mEq/L, as well as biochemical evidence of poorer disease control despite associated greater medication use. Individualization of dialysate calcium concentration rather than predominant use of dialysate calcium concentrations &lt; 2.50 mEq/L should be considered.</description><subject>Aged</subject><subject>Biomarkers - blood</subject><subject>Calcium - analysis</subject><subject>Calcium - blood</subject><subject>Cause of Death</subject><subject>Cohort Studies</subject><subject>dialysate calcium concentration</subject><subject>dialysate composition</subject><subject>End-stage renal disease (ESRD)</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>heart failure</subject><subject>Heart Failure - etiology</subject><subject>Heart Failure - mortality</subject><subject>Hemodialysis Solutions - adverse effects</subject><subject>Hemodialysis Solutions - chemistry</subject><subject>Hemodialysis Units, Hospital</subject><subject>Humans</subject><subject>hypocalcemia</subject><subject>intradialytic hypertension</subject><subject>Kidney Failure, Chronic - blood</subject><subject>Kidney Failure, Chronic - mortality</subject><subject>Kidney Failure, Chronic - therapy</subject><subject>Linear Models</subject><subject>Male</subject><subject>Medicare</subject><subject>metabolic bone disease</subject><subject>Middle Aged</subject><subject>mortality</subject><subject>Myocardial Infarction - etiology</subject><subject>Myocardial Infarction - mortality</subject><subject>Nephrology</subject><subject>Poisson Distribution</subject><subject>Prognosis</subject><subject>Renal Dialysis - adverse effects</subject><subject>Renal Dialysis - methods</subject><subject>Retrospective Studies</subject><subject>Risk Assessment</subject><subject>secondary hyperparathyroidism</subject><subject>Stroke - etiology</subject><subject>Stroke - mortality</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><subject>United States</subject><issn>0272-6386</issn><issn>1523-6838</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kt2KFDEQhYMo7rj6Al5ILr3pMT_d6YyIMIyuKyzM4up1SCfVkt7-GZPugX4A39tqZ3YvvBACgapzDqmvQshrztacFfJds7bNvV8Lxos1k3j0E7LihZCZ0lI_JSsmSpEpqdUFeZFSwxjbSKWekwuh0CPKfEV-X1kX2jDO9FOw7ZzsCHRnWxemjt5G68bgIFHbe7prQx-cbel-Gt3QYXXbDf1PemvHAP2Y6DdwEI4BS9fQDf5vXEjv6RY7YxzSATDtCHRfJYhHdA09pt2Nk59fkme1bRO8Ot-X5MfV5--76-xm_-XrbnuTuVzzMSuV4oxvODCvC5VD4TSITcEFl7USXleVdk6XZcGcw561smZKM7SoCnwN8pK8PeUe4vBrgjSaLiQHbWt7GKZkeMnVRuZsw1AqTlKHT08RanOIobNxNpyZBb9pzILfLPgNk3g0mt6c86eqA_9oeeCNgg8nAeCUxwDRJIf0HPgQEY_xQ_h__sd_7O68lXuYITXDFJEpzmGSMMzcLR9g2T8vGFO5kPIPy9CswQ</recordid><startdate>20151001</startdate><enddate>20151001</enddate><creator>Brunelli, Steven M., MD, MSCE</creator><creator>Sibbel, Scott, PhD, MPH</creator><creator>Do, Thy P., PhD, MPH</creator><creator>Cooper, Kerry, MD</creator><creator>Bradbury, Brian D., DSc</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20151001</creationdate><title>Facility Dialysate Calcium Practices and Clinical Outcomes Among Patients Receiving Hemodialysis: A Retrospective Observational Study</title><author>Brunelli, Steven M., MD, MSCE ; Sibbel, Scott, PhD, MPH ; Do, Thy P., PhD, MPH ; Cooper, Kerry, MD ; Bradbury, Brian D., DSc</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c481t-76610191e0d8564e5c8e2951213f62d8bb8cc87750cc5c8aa3f06800196bedfe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Aged</topic><topic>Biomarkers - blood</topic><topic>Calcium - analysis</topic><topic>Calcium - blood</topic><topic>Cause of Death</topic><topic>Cohort Studies</topic><topic>dialysate calcium concentration</topic><topic>dialysate composition</topic><topic>End-stage renal disease (ESRD)</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>heart failure</topic><topic>Heart Failure - etiology</topic><topic>Heart Failure - mortality</topic><topic>Hemodialysis Solutions - adverse effects</topic><topic>Hemodialysis Solutions - chemistry</topic><topic>Hemodialysis Units, Hospital</topic><topic>Humans</topic><topic>hypocalcemia</topic><topic>intradialytic hypertension</topic><topic>Kidney Failure, Chronic - blood</topic><topic>Kidney Failure, Chronic - mortality</topic><topic>Kidney Failure, Chronic - therapy</topic><topic>Linear Models</topic><topic>Male</topic><topic>Medicare</topic><topic>metabolic bone disease</topic><topic>Middle Aged</topic><topic>mortality</topic><topic>Myocardial Infarction - etiology</topic><topic>Myocardial Infarction - mortality</topic><topic>Nephrology</topic><topic>Poisson Distribution</topic><topic>Prognosis</topic><topic>Renal Dialysis - adverse effects</topic><topic>Renal Dialysis - methods</topic><topic>Retrospective Studies</topic><topic>Risk Assessment</topic><topic>secondary hyperparathyroidism</topic><topic>Stroke - etiology</topic><topic>Stroke - mortality</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Brunelli, Steven M., MD, MSCE</creatorcontrib><creatorcontrib>Sibbel, Scott, PhD, MPH</creatorcontrib><creatorcontrib>Do, Thy P., PhD, MPH</creatorcontrib><creatorcontrib>Cooper, Kerry, MD</creatorcontrib><creatorcontrib>Bradbury, Brian D., DSc</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of kidney diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brunelli, Steven M., MD, MSCE</au><au>Sibbel, Scott, PhD, MPH</au><au>Do, Thy P., PhD, MPH</au><au>Cooper, Kerry, MD</au><au>Bradbury, Brian D., DSc</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Facility Dialysate Calcium Practices and Clinical Outcomes Among Patients Receiving Hemodialysis: A Retrospective Observational Study</atitle><jtitle>American journal of kidney diseases</jtitle><addtitle>Am J Kidney Dis</addtitle><date>2015-10-01</date><risdate>2015</risdate><volume>66</volume><issue>4</issue><spage>655</spage><epage>665</epage><pages>655-665</pages><issn>0272-6386</issn><eissn>1523-6838</eissn><abstract>Background Some US dialysis facilities have reduced default dialysate calcium concentrations from 2.5 mEq/L to lower levels. There has been no rigorous systematic examination of the effects of such a reduction on clinical and biochemical outcomes. Study Design Retrospective cohort study. Setting &amp; Participants Medicare-eligible patients who received in-center hemodialysis at a large dialysis organization in January 2008 to December 2010. Predictor Facility conversion from predominant use (≥75% patients) of 2.50-mEq/L dialysate calcium to predominant use of lower dialysate calcium concentrations versus maintenance of predominant use of 2.50-mEq/L dialysate calcium. Outcomes All-cause and cause-specific mortality and hospitalization, laboratory markers of metabolic bone disease, and drug utilization. Measurements Hierarchical mixed linear and Poisson models were fit to compare pre- to postconversion differences in outcomes between converter and matched control facilities. Results, expressed as relative rate ratios (RRRs) and delta-delta (change in mean values), were estimated for early (months 0-2) and late (months 3-12) postconversion to allow for possible latent effects. Results Facility conversion was associated with greater rates of hospitalization for heart failure exacerbation (late RRR, 1.27 [95% CI, 1.06-1.51]), hypocalcemia (early RRR, 1.19 [95% CI, 1.05-1.35]; late RRR, 1.39 [95% CI, 1.20-1.60]), and intradialytic hypotension (early RRR, 1.07 [95% CI, 1.02-1.11]; late RRR, 1.05 [95% CI, 1.01-1.10]), but no differences were observed for all-cause mortality or hospitalization rates. Facility conversion was also associated with comparative temporal decreases in serum calcium level, increases in serum phosphate and parathyroid hormone levels, and increases in use of phosphate binders, vitamin D, and calcimimetics. Limitations Possible residual confounding, generalizability beyond Medicare patients uncertain. Conclusions There are potential safety concerns associated with the default use of dialysate calcium concentrations &lt; 2.50 mEq/L, as well as biochemical evidence of poorer disease control despite associated greater medication use. Individualization of dialysate calcium concentration rather than predominant use of dialysate calcium concentrations &lt; 2.50 mEq/L should be considered.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>26015274</pmid><doi>10.1053/j.ajkd.2015.03.038</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0272-6386
ispartof American journal of kidney diseases, 2015-10, Vol.66 (4), p.655-665
issn 0272-6386
1523-6838
language eng
recordid cdi_proquest_miscellaneous_1716934090
source MEDLINE; Elsevier ScienceDirect Journals
subjects Aged
Biomarkers - blood
Calcium - analysis
Calcium - blood
Cause of Death
Cohort Studies
dialysate calcium concentration
dialysate composition
End-stage renal disease (ESRD)
Female
Follow-Up Studies
heart failure
Heart Failure - etiology
Heart Failure - mortality
Hemodialysis Solutions - adverse effects
Hemodialysis Solutions - chemistry
Hemodialysis Units, Hospital
Humans
hypocalcemia
intradialytic hypertension
Kidney Failure, Chronic - blood
Kidney Failure, Chronic - mortality
Kidney Failure, Chronic - therapy
Linear Models
Male
Medicare
metabolic bone disease
Middle Aged
mortality
Myocardial Infarction - etiology
Myocardial Infarction - mortality
Nephrology
Poisson Distribution
Prognosis
Renal Dialysis - adverse effects
Renal Dialysis - methods
Retrospective Studies
Risk Assessment
secondary hyperparathyroidism
Stroke - etiology
Stroke - mortality
Survival Analysis
Treatment Outcome
United States
title Facility Dialysate Calcium Practices and Clinical Outcomes Among Patients Receiving Hemodialysis: A Retrospective Observational Study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T19%3A37%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Facility%20Dialysate%20Calcium%20Practices%20and%20Clinical%20Outcomes%20Among%20Patients%20Receiving%20Hemodialysis:%20A%20Retrospective%20Observational%20Study&rft.jtitle=American%20journal%20of%20kidney%20diseases&rft.au=Brunelli,%20Steven%20M.,%20MD,%20MSCE&rft.date=2015-10-01&rft.volume=66&rft.issue=4&rft.spage=655&rft.epage=665&rft.pages=655-665&rft.issn=0272-6386&rft.eissn=1523-6838&rft_id=info:doi/10.1053/j.ajkd.2015.03.038&rft_dat=%3Cproquest_cross%3E1716934090%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1716934090&rft_id=info:pmid/26015274&rft_els_id=S0272638615006423&rfr_iscdi=true